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-erbB receptors are usually located in cell membranes
and are activated by extracellular binding of EGF-like
growth factors. Unexpectedly, using immunoﬂuorescence
we found high levels of c-erbB-3 within the nuclei of
MTSV1-7 immortalized nonmalignant human mammary
epithelial cells. Nuclear localization was mediated by the
COOH terminus of c-erbB-3, and a nuclear localization
signal was identiﬁed by site-directed mutagenesis and by
transfer of the signal to chicken pyruvate kinase. A nuclear
export inhibitor caused accumulation of c-erbB-3 in the
nuclei of other mammary epithelial cell lines as demonstrated
by immunoﬂuorescence and biochemical cell fractionation,
c
 
suggesting that c-erbB-3 shuttles between nuclear and non-
nuclear compartments in these cells. Growth of MTSV1-7
on permeable ﬁlters induced epithelial polarity and concen-
tration of c-erbB-3 within the nucleoli. However, the c-erbB-3
ligand heregulin 
 
 
 
1 shifted c-erbB-3 from the nucleolus
into the nucleoplasm and then into the cytoplasm. The
subcellular localization of c-erbB-3 obviously depends on
exogenous stimuli and on the stage of epithelial polarity
and challenges the speciﬁc function of c-erbB-3 as a
transmembrane receptor protein arguing for additional, as
yet unidentiﬁed, roles of c-erbB-3 within the nucle(ol)us of
mammary epithelial cells.
 
Introduction
 
c-erbB-1 to -4 are generally considered as transmembrane
receptors, which usually exert their activities through extra-
cellular binding of EGF-like growth factors. Ligand-stimulated
c-erbB-1, -2, and -4 phosphorylate themselves and other
cytoplasmic substrates at tyrosine residues, thus activating
an intracellular signaling cascade. c-erbB-1 and -2 represent
useful parameters for the prognosis of malignant diseases
(Grunt and Huber, 1994) and are used as target structures
for anticancer therapeutics (Shepard et al., 1991; Osherov et
al., 1993). Heregulin (HRG)* binds to c-erbB-3 or -4 and
induces heterodimerization of these receptors with c-erbB-2.
The latter thus represents an orphan receptor that does not
bind HRG on its own but reveals potent tyrosine kinase ac-
tivity and acts as a coreceptor molecule that is crucial for
HRG-dependent signaling. c-erbB-3, like the other c-erbB
receptors, contains one predicted transmembrane domain
(MALTVIAGLVVIFMMLGGTFL, amino acids 644–664),
 
but in contrast to the other members it does not have a
functional tyrosine kinase domain (Guy et al., 1994).
Thus, c-erbB-3 requires a heterodimer partner for tyrosine
kinase signaling. The COOH terminus of c-erbB-3, in turn,
reveals potent signaling capability by direct recruitment of
phosphatidylinositol 3-kinase and Shc (Waterman et al.,
1999). All c-erbB receptors can form functionally active het-
erodimers (Riese et al., 1996). However, the described activi-
ties explain why the c-erbB-2/-3 dimer constitutes the most
active c-erbB receptor complex (Pinkas-Kramarski et al.,
1996). c-erbB-3, unlike c-erbB-2, is present in most human
tissues (Prigent et al., 1992). In breast cancer cells, both can
be overexpressed/activated separately or jointly, can cooperate
during transformation and progression (Kraus et al., 1989,
1993; Lemoine et al., 1992; Rajkumar and Gullick, 1994;
Alimandi et al., 1995), and can be found not only in the cell
membrane but also in intracellular compartments (Kumar et
al., 1991; Lemoine et al., 1992).
Nontumorigenic MTSV1-7 cells represent milk derived,
SV40 large T antigen–immortalized, nonmalignant human
mammary epithelial cells that express cytokeratins 7, 8, 18,
and 19 and reveal a morphology, which is indicative of their
luminal origin (Bartek et al., 1991).
Here we demonstrate nuclear localization of c-erbB-3 in
MTSV1-7 and in human breast cancer cells, which is due to
an active nuclear localization signal (NLS) near the COOH
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terminus of the protein. Moreover, c-erbB-3 was found in
the nucleoli of differentiated polarized MTSV1-7 and ex-
ported into the cytoplasm upon addition of exogenous HRG.
 
Results
 
Nuclear localization of c-erbB-3
 
Subcellular distribution of c-erbB-3 was examined in
MTSV1-7 cells by confocal immunofluorescence microscopy
and immuno EM. Fig. 1 A reveals nuclear immunofluores-
cence obtained with three different c-erbB-3–specific anti-
bodies: a monoclonal antibody directed against a cytoplasmic
epitope of c-erbB-3 (RTJ2) produced a strong nuclear signal
(Fig. 1 A, a); staining of the nuclei was slightly less intense
when polyclonal antibodies reacting either with a domain
close to the extracellular NH
 
2
 
 terminus (Ab-9) (Fig. 1 A, b)
or with the cytoplasmic COOH terminus of c-erbB-3 (C17)
(Fig. 1 A, c) were used. It has to be noted that Ab-9 also
weakly labeled some cytoplasmic and membrane sites (Fig. 1
A, b). Equivalent staining was obtained with three different
Figure 1. Nuclear localization of 
c-erbB-3 in MTSV1-7. (A) Confocal 
immunofluorescent microscopy demon-
strating nuclear c-erbB-3 using the 
monoclonal RTJ2 antibody directed 
against a cytoplasmic epitope of c-erbB-3 
(a) or polyclonal antibodies against an 
NH2- (b, Ab-9) or COOH-terminal 
domain (c, C17). Note in panel b some 
cytoplasmic and membrane staining is 
also seen. Bar, 25  m. (B) Immuno EM 
using RTJ2 (a–c) and Ab-9 (d) revealing 
nuclear (a and d), cytoplasmic (b and d), 
and cell membrane-located (c and d) 
c-erbB-3 (arrows). np, nucleoplasm; cp, 
cytoplasm. Bars, 0.1  m. 
 
 
c-erbB-3: a nuclear protein |
 
 Offterdinger et al. 931
 
protocols for cell fixation and permeabilization (unpublished
data). The data suggest that nuclear c-erbB-3 is not truncated
but rather represents the full-length protein and that the oc-
currence of c-erbB-3 in the nuclei is not an artifact caused by
the cell preparation. This specific pattern of subcellular distri-
bution of c-erbB-3 was further confirmed by immuno EM.
Nuclear staining was obtained with the RTJ2 and Ab-9 anti-
bodies (Figs. 1 B, a and d), respectively. Moreover, both anti-
bodies also labeled some cytoplasmic (Figs. 1 B, b and d) and
cell membrane sites (Figs. 1 B, c and d). Two other antibod-
ies gave only very weak (C17) or no signals at all (SGP1) und
thus were not suitable for EM (unpublished data).
A quantitative analysis of these data (Table I) demon-
strates that both RTJ2 and Ab-9 preferentially stain the nu-
clei of MTSV1-7 cells, although at varying relative intensi-
ties. For RTJ2, the mean nuclear/nonnuclear distribution of
the immunogold label was 
 
 
 
15:1, whereas for Ab-9 it was
1.8:1. The intensity of the total (nucleus plus cytoplasm)
background signal was 
 
 
 
1% of the total stains obtained
with RTJ2 and Ab-9, respectively, and with both antibodies
label density in the cytoplasm was significantly higher than
that in the cytoplasm of the negative controls (Table I).
We hypothesized that nuclear localization might be a gen-
eral property of c-erbB-3. Therefore, a panel of nonmalig-
nant and malignant human mammary epithelial cells was
subjected to immunofluorescence microscopy in the absence
or presence of the nuclear export inhibitor leptomycin B
(LMB). This drug specifically blocks the chromatin region
maintenance (CRM)1 nuclear export factor by covalent
modification (Kudo et al., 1999). In MCF10A, MCF-7,
T47D (Fig. 2 A), and BT474 cells (unpublished data), LMB
clearly caused nuclear concentration of c-erbB-3. In BT20
and MDA468 cells, nuclear staining was strong already in
the absence of LMB and was not further intensified by LMB
(Fig. 2 A). Similar results were obtained in MTSV1-7 (un-
published data). BT483 revealed a very low growth rate
(splitting ratio 1:2 per 2 wk) and was the only cell line
that showed neither spontaneous nor LMB-induced nuclear
c-erbB-3 staining. Instead, BT483 showed cytoplasmic and
plasma membrane staining for c-erbB-3 (Fig. 2 A). Fig. 2 B
demonstrates the subcellular distribution of transiently ex-
pressed FLAG-tagged c-erbB-3 in MCF-7 cells after immu-
nolabeling with an anti-FLAG antibody. Vehicle-treated
control cells revealed predominantly cytoplasmic staining,
whereas LMB-exposed (5 ng/ml, 24 h) MCF-7cells dis-
played nuclear accumulation of c-erbB-3–FLAG. Interest-
ingly, c-erbB-2, representing the most important hetero-
dimer partner of c-erbB-3, did not localize to the nucleus of
any of the cell lines tested neither spontaneously nor after
LMB treatment and independent of the level of spontaneous
expression (unpublished data).
Surprisingly, although c-erbB-3 is known as a transmem-
brane protein, c-erbB-3–specific immunofluorescent label-
ing at the surface membranes was barely visible in most cell
lines studied. Outshining effects due to more prominent
nuclear and cytoplasmic immunostaining might partially
cause this. Therefore, nonpermeabilized cells were subjected
to flow cytometry using the SGP1 monoclonal antibody,
which recognizes an extracellular epitope of c-erbB-3. All
cells were life gated with propidium iodide in order to ex-
clude intercellular staining of nonviable cells.
Table II demonstrates that all cell lines analyzed except
BT20 contained c-erbB-3 within the surface membrane, al-
beit at varying intensities.
Next, we wanted to confirm the nuclear expression of
c-erbB-3 by using a nonmicroscopy-based system. To this
end, proteins from MCF-7 cell lysates were subjected to sub-
 
Table I. 
 
Quantification of label density distribution after immuno 
EM using c-erbB-3 specific antibodies
 
a
 
Antibody Mean label density (SD)
Nucleus Cytoplasm
 
RTJ2 55.06 (48.72) 3.60 (2.91)*
Ab-9 46.81 (37.12) 26.62 (16.93)**
Control 0.30 (0.96) 0.35 (0.63)
 
a
 
Signal density after immunostaining with monoclonal RTJ2, polyclonal
Ab-9, or without first antibody (control) was evaluated as gold grains per
nuclear and cytoplasmic area of 10 randomly chosen cells per sample
([number of gold grains/µm
 
2
 
] 
 
 
 
 100). High values for SDs are due to vari-
ability of total cellular label densities amongst individual cells. The nuclear
label density produced by RTJ2 consistently was between 82 and 95% of
the total cellular label density, whereas for Ab-9 it ranged from 65 to 84%.
Cytoplasmic label densities in the presence of RTJ2 and Ab-9 were
significantly higher than in controls as evaluated with Student’s 
 
t
 
 test. *
 
P
 
 
 
 
 
0.01; **
 
P
 
 
 
 
 
 0.001.
Figure 2. Effects of LMB on the subcellular distribution of c-erbB-3 
using confocal immunofluorescence microscopy. (A) Various cell 
lines were treated for 24 h with solvent ( ) or 20 ng/ml LMB ( ) 
and immunostained using RTJ2. Bar, 25  m. (B) MCF-7 cells were 
transiently transfected with FLAG-tagged c-erbB-3, treated for 24 h 
with solvent (Control) or 5 ng/ml LMB, and immunostained with M2 
anti-FLAG antibody. Bar, 5  m. 
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cellular fractionation followed by immunoprecipitation and
Western blotting. Cytoplasmic-enriched (C) and nuclear-
enriched (N) protein fractions of untreated and LMB-
treated (24 h, 5 ng/ml) MCF-7 cells were precipitated with a
monoclonal antibody against the extracellular domain of
c-erbB-3 (SGP1) followed by blotting with an affinity puri-
fied polyclonal antibody against an intracellular peptide of
c-erbB-3 (C17). Fig. 3 A demonstrates that LMB induced a
significant shift of c-erbB-3 from the C into the N fraction.
Densitometric quantitation of the band intensities in C and
N was done, and the relative distribution between the com-
partments was expressed as a C to N ratio, which dropped
from 3.0 before LMB to 
 
 
 
0.8 after LMB treatment. Equiv-
alent results were obtained when c-erbB-3 was probed by
Western blotting without immunoprecipitation (C17 only)
(Fig. 3 B). The purity of the fractions was estimated by
probing Western blot membranes for the following marker
proteins (Fig. 3 B): pyruvate kinase (cytoplasm), histone H1
(nucleus), calnexin (ER membrane), and transferrin receptor
(plasma membrane). Fig. 3 B demonstrates that there was
virtually no cross-contamination of soluble proteins between
C and N, whereas ER and plasma membrane constituents
were found in both fractions. However, most importantly
LMB treatment did not affect the distribution of any of
these membrane marker proteins, indicating that the LMB-
induced enrichment of c-erbB-3 in N is independent of the
membrane components found in this fraction. Omission of
Triton X-100 from the cytoplasmic extract buffer during the
preparation of C caused an almost complete disappearance
of c-erbB-3–specific immunoreactive material in this frac-
tion as demonstrated by blotting with the C17 antibody
(Fig. 3 C, first compared with second lane). Instead, high
amounts of c-erbB-3 were recovered from the corresponding
Triton X-100–free membrane pellet after centrifugation at
100,000 
 
g
 
 (Fig. 3 C, third lane). However, a direct quantita-
tive comparison of c-erbB-3 in the membrane pellet and in
the Triton X-100–treated cytoplasmic fraction is inappro-
priate, since an arbitrary amount of the membrane pellet was
loaded onto the gel. These data indicate that c-erbB-3 found
in fraction C is primarily membrane bound.
 
Secretion of endogenous HRG
 
HRG represents the cognate ligand of c-erbB-3 causing het-
erodimerization of c-erbB-3 with c-erbB-2 and activation of
the receptor complex. This growth factor was found to be
expressed in mammary tissues. Therefore, serum-free culture
supernatants from MTSV1-7 and MCF10A cell cultures
were tenfold concentrated and subjected to SDS-PAGE fol-
lowed by immunoblotting for HRG. Fig. 4 demonstrates
that confluent monolayers of MTSV1-7 cells but not of
MCF10A cells secrete an immunoreactive protein of the ex-
pected size (44 kD), indicating that MTSV1-7 cells express
endogenous HRG, whereas MCF10A cells do not produce
detectable amounts of this growth factor.
 
Effects of exogenous HRG
 
 
 
1
 
We hypothesized that HRG, which profoundly affects
c-erbB-3 function, might also regulate its subcellular distri-
bution. It has to be noted that c-erbB-3, although found pri-
marily within the nuclei, was concomitantly seen in variable
amounts within the cytoplasm and at the cell membrane as
well (Fig. 1 A, b, and B, b–d, Fig. 2 A, Fig. 3, and Tables I
and II). This might partially be caused by autocrine activa-
tion of c-erbB-3 via endogenous HRG. Permeable filters, in
contrast to solid substrate, provide a polarizing environment
 
Table II.
 
 Cell surface expression of c-erbB-3 as demonstrated by 
flow cytometry
 
a
 
Cell line MFI
 
b
 
mIgG c-erbB-3
 
MCF-7 2.09 17.20
MDA468 3.22 11.74
T47D 1.76 4.81
BT20 2.01 2.54
 
a
 
A minimum of 5,000 nonpermeabilized cells was stained with murine
IgG or with SGP1 anti–c-erbB-3 and anti–mouse Ig Alexa 488 conjugate.
Life gating with propidium iodide was performed in order to exclude per-
meable cells from analysis.
 
b
 
MFI, mean fluorescence intensity (arbitrary units).
Figure 3. Immunochemical demonstration of c-erbB-3 in MCF-7 
cells. (A) 400  g protein from untreated ( ) or LMB-treated ( ) C or 
N MCF-7 fractions were immunoprecipitated (IP) with SGP1, which 
detects an extracellular epitope of c-erbB-3, or with mIgG1 and 
blotted (IB) with C17, which binds to the cytoplasmic part of 
c-erbB-3. (B) 20  g total protein from each fraction (C or N) were 
blotted with anti–c-erbB-3 (C17), antipyruvate kinase, anti–histone 
H1, anticalnexin, or antitransferrin receptor. Note calnexin has an 
apparent molecular mass of 90 kD (arrow). The bottom band seen 
in N represents a nonspecifically stained bulk nuclear protein. (C) 
Cytoplasmic-enriched fractions were prepared with or without the 
addition of 0.2% Triton X-100 and blotted for c-erbB-3 (C17). After 
centrifugation at 100,000 g, an arbitrary amount of the membrane 
pellet (M) from the fraction prepared without Triton X-100 was 
loaded as a control. 
 
 
c-erbB-3: a nuclear protein |
 
 Offterdinger et al. 933
 
for epithelial cells and caused MTSV1-7 cells not only to dif-
ferentiate and to develop epithelial polarity as determined by
localization of E-cadherin and ZO-1 (unpublished data) and
by the presence of microvilli (Fig. 5 C, 24 h) but also to re-
spond to exogenous HRG by a time-dependent export of
c-erbB-3 into nonnuclear compartments, which was completed
by 
 
 
 
24 h (Fig. 5, A–C). However, under HRG-free condi-
tions (no HRG added and endogenous HRG blocked by
anti-HRG) c-erbB-3 was concentrated in the granular com-
ponent of the nucleoli (Fig. 5 A, 0 min, and C, 0 min) being
the site of rRNA processing and preribosome formation. Af-
ter 1 h of exposure to exogenous HRG
 
 
 
1, a mixed nucleolar/
nuclear staining pattern became evident, and after 4 h a cyto-
plasmic staining pattern became evident, which was com-
pleted by 24 h with no further change upon longer exposure
(Fig. 5, A–C). Cells not blocked with anti-HRG exhibited a
small amount of cytoplasmic c-erbB-3, which may be caused
by endogenous HRG, and responded similarly to exogenous
HRG
 
 
 
1 (Fig. 5 B). Endogenous HRG was below the detec-
tion limit of confocal immunofluorescence microscopy in
Figure 4. Immunochemical analysis of HRG secretion from 
MTSV1-7 and MCF10A cells. Concentrated serum-free supernatants 
from cell-free (0), subconfluent (sub), and confluent (con) MTSV1-7 
or MCF10A cultures were blotted with anti-pan HRG.
Figure 5. HRG 1 affects subcellular 
distribution of c-erbB-3. MTSV1-7 were 
examined by confocal immunofluores-
cent microscopy (A,B, and D) and 
immuno EM (C) for c-erbB-3 (A–C) or 
HRG (D). (A) Cells on filters pretreated 
with neutralizing anti-HRG (10  g/ml, 
48 h) were exposed for various times to 
1 nM HRG 1. Note mitotic cells were 
strongly positive. (B) Endogenous HRG 
was not blocked by anti-HRG (0 min) 
before exogenous HRG 1 (1 nM, 48 h). 
(C) 0 min, after blocking of endogenous 
HRG, c-erbB-3 (arrows) was found in the 
granular component (gc) of the nucleolus 
(nc). np, nucleoplasm. At 24 h, added 
HRG 1 (1 nM) caused relocation of 
c-erbB-3 into the cytoplasm (cp) and 
to the cell membrane. (D) Cells were 
treated as in B but immunostained with 
anti-pan HRG. Bars: (A, B, and D) 40 
 m; (C) 0.1  m. 
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untreated MTSV1-7 cells, whereas added HRG
 
 
 
1 was seen
readily in the cytoplasm but not in the nucleus during the
whole observation period of 48 h (Fig. 5 D).
 
NLS within c-erbB-3
 
Nuclear localization is usually mediated by specific, short ba-
sic amino acid sequences within nuclear proteins (nuclear lo-
calization signals [NLSs]). Therefore, we analyzed the c-erbB-3
protein sequence for the presence of such sequences. Using
PSORT II software (http://psort.nibb.ac.jp), we identified
two potential NLSs within the c-erbB-3 protein (NLS-1,
RPRR and NLS-2, RRRR). To directly determine the func-
tional significance of these two NLSs, we ligated different c-
erbB-3 cDNA fragments containing either NLS-1 or NLS-2
coding sequences to enhanced green fluorescent protein
(EGFP) and transfected them into MTSV1-7 cells. Fig. 6 A, a,
demonstrates that the complete NH
 
2
 
-terminal part of c-erbB-3
containing NLS-1 (amino acids 1–1,088, yielding a 158-kD
fusion protein) was unable to target EGFP into the nucleus.
Deletion of all but the first 74 amino acids of c-erbB-3 (amino
acids 1-74, yielding a 36-kD fusion protein) led to a mixed
cytoplasmic and nuclear localization of the construct (Fig. 6
A, b). The size exclusion limit of the nuclear pore complex is
 
 
 
60 kD. Therefore, nuclear entry of the small fusion protein
(36 kD) is most likely caused by passive diffusion through the
nuclear pore complexes. In contrast, fusing the COOH termi-
nus of c-erbB-3 containing NLS-2 (amino acids 1,089–
1,323) to EGFP yielded a 55-kD protein, which was concen-
trated in the cell nucleus (Fig. 6 A, c). Semiquantitative analy-
sis of the distribution of the recombinant proteins between
the two compartments was done by image analysis as de-
scribed and shown in Fig. 6 B. Site-directed mutagenesis of
NLS-2 (RRRR to RSGR) reduced nuclear localization to lev-
els which were similar to those seen for the 36-kD construct
(Fig. 6 A, d compared with b, and 6 B, d compared with b).
Transfer of a sequence containing NLS-2 (RRRRHSP*)
of c-erbB-3 to chicken pyruvate kinase (CPK), an exclusively
cytoplasmic protein, further confirmed that NLS-2 is re-
sponsible for nuclear targeting of c-erbB-3. Confocal immu-
nofluorescence microscopy revealed that transfected wild-
type CPK localizes to the cytoplasm of MTSV1-7 cells (Fig.
7 A, CPK). However, fusing the control NLS of human
lamin C to CPK causes CPK to enter the nucleus of
MTSV1-7 cells (Fig. 7 A, CPK-CoNLS). Most importantly,
NLS-2 of human c-erbB-3 (Fig. 7 A, CPK-NLS-2) or the
complete COOH terminus of c-erbB-3 (amino acids 1,089–
1,323) (Fig. 7 A, CPK-erbB3CT) were as active in targeting
CPK to the nucleus of MTSV1-7 cells as the control NLS of
human lamin C. Semiquantitative evaluation of the subcel-
lular distribution of these constructs was done by image
analysis as described and shown in Fig. 7 B.
 
Discussion
 
Spontaneous and LMB-induced nuclear localization 
of p185
 
c-erbB-3
 
This report provides the first evidence that c-erbB-3 can be
localized in the nucleus of normal and malignant human
mammary epithelial cells. The specific subcellular distribu-
tion was independent of the cell fixation procedure and
of the individual antibodies used. In particular, nuclear
localization of c-erbB-3 was observed in nonmalignant
MTSV1-7 cells by confocal immunofluorescence micros-
copy using one monoclonal (RTJ2) and two different poly-
clonal antibodies (Ab-9 and C17) directed either against a
cytoplasmic epitope located next to the very COOH termi-
nus (C17) or more upstream from it (RTJ2), or against a
domain near the NH
 
2
 
 terminus (Ab-9) of c-erbB-3. These
data were further confirmed by immuno EM using RTJ2
and Ab-9 (Fig. 1).
Figure 6. NLS-2 is functional in c-erbB-3. 
(A) MTSV1-7 transiently transfected with 
EGFP–mutant-erbB-3 fusion constructs. 
Removal of NLS-2 by COOH-terminal 
truncation completely precluded nuclear 
localization of the protein in A, panel a 
(158 kD; larger than the size exclusion 
limit of the nuclear pore complex, which 
is  60 kD), whereas the smaller construct 
in A, panel b (36 kD) can be found in 
both compartments. The COOH-terminal 
fragment containing NLS-2 (55 kD) is 
concentrated in the nuclei (A, c).
Inactivating mutation of NLS-2 (mutNLS-2) 
partially reverts nuclear concentration 
(A, d). Bar, 25  m. (B) At least four 
independent points, randomly chosen in 
each compartment (C, cytoplasm; N, 
nucleus), were measured in arbitrary 
units (pixel intensity), and relative 
antigen staining was expressed for 
each compartment in percent of total 
(C   N, means   SD). 
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RTJ2 seemed to detect nuclear c-erbB-3 with higher affin-
ity and specificity than the other antibodies tested. This
might be due to a different conformation of nuclear c-erbB-3
when compared with nonnuclear c-erbB-3, thereby better
exposing the particular epitope recognized by RTJ2. There-
fore, RTJ2 was chosen for the majority of our immunofluo-
rescence experiments. Our data indicate that RTJ2 does not
cross-react with some unrelated nuclear bulk protein nor
does it selectively detect nuclear c-erbB-3 only. First, nuclear
localization of c-erbB-3 was also seen with additional poly-
clonal antibodies, which recognize unrelated epitopes (Fig.
1, A and B). Second, RTJ2 similarly labeled nonnuclear
c-erbB-3 (Fig. 1 B, Fig. 2, BT483, and Fig. 5).
Nuclear staining of variable intensity was also seen in
other nonmalignant and malignant human mammary epi-
thelial cells and was found to be strictly dependent on the
applied culture conditions. For instance, the nuclear export
inhibitor LMB (Fukuda et al., 1997) caused a significant en-
richment of c-erbB-3 in the nuclei of cell lines that otherwise
revealed only low levels of nuclear staining (Fig. 2 A). A sim-
ilar effect was observed when MCF-7 cells were transiently
transfected with full-length c-erbB-3 tagged with the FLAG
peptide followed by LMB treatment and immunofluorescent
detection of the receptor using the M2 anti-FLAG antibody
(Fig. 2 B). This is in accordance with data obtained by im-
munoprecipitation and Western blotting of C and N frac-
tions from untreated and LMB-treated MCF-7 cells, which
revealed a significant LMB-induced deprivation of c-erbB-3
in C and a concurrent enrichment in N (Fig. 3). Although
we cannot entirely exclude that some c-erbB-3 found in the
C fraction might come from leakage of the receptor from the
nucleus during cell lysis and fractionation, several lines of ev-
idence yet argue against this. First, analysis of the purity of
the fractions revealed that there was virtually no cross-con-
tamination of soluble proteins between C and N as indicated
by the distribution of the nuclear protein histone H1 and the
cytoplasmic marker pyruvate kinase (Fig. 3 B). Second, the
data in Fig. 3 C demonstrate that “cytoplasmic” c-erbB-3 is
primarily membrane bound in MCF-7 cells. Moreover, it is
important to note that LMB did not affect the distribution
of the membrane marker proteins calnexin and transferrin
receptor between C and N, although it still caused cytoplas-
mic deprivation and nuclear accumulation of c-erbB-3, indi-
cating that contaminating membrane components are not a
major source for the presence of c-erbB-3 in N. Interestingly,
the molecular mass of nuclear c-erbB-3 was 
 
 
 
185 kD. Thus
the nuclear species represents the full-length protein and not
a truncated version of c-erbB-3.
Although cell surface labeling for c-erbB-3 was rather
weak in immunofluorescence microscopy, flow cytometry
clearly demonstrated that c-erbB-3 can be detected in the
plasma membrane. Despite general paucity of reports on the
subcellular distribution of c-erbB receptors, there is one pa-
per (Xie and Hung, 1994) describing partial nuclear local-
ization of low levels of c-neu, the rat homologue of human
c-erbB-2, in rat DHFR/G8 cells. Another study (Srinivasan
et al., 2000) demonstrated nuclear localization of c-erbB-4
in primary human breast cancers, which might be caused by
a potential NLS within the c-erbB-4 amino acid sequence.
These data are supported by a very recent report from Ni et
al. (2001), who demonstrated that the intracellular domain
of c-erbB-4 gets cleaved by 
 
 
 
-secretase. The truncated cyto-
plasmic fragment then translocates into the nucleus (Ni et
al., 2001). In addition, Lin et al. (2001) reported nuclear lo-
calization of c-erbB-1 in several malignant cell lines and
presented evidence suggesting that nuclear c-erbB-1 might
function as a transcription factor. In contrast to c-erbB-4
but in accordance with our data on c-erbB-3 nuclear c-erbB-1
Figure 7. NLS-2 is sufficient for nuclear 
targeting. (A) MTSV1-7 transiently trans-
fected with CPK fusion constructs. CPK 
alone localizes to the cytoplasm (CPK), 
whereas the control NLS of human 
lamin C (CPK-CoNLS) mediates efficient 
nuclear targeting of CPK. NLS-2 of 
human c-erbB-3 (CPK-NLS-2), consisting 
of the sequence RRRRHSP*, efficiently 
localizes CPK to the nucleus. The same 
is true for the complete COOH terminus 
of c-erbB-3 (CPK-erbB3CT). Bar, 25  m. 
(B) Quantitation (performed as in 6 B) 
demonstrated that NLS-2 and the COOH 
terminus of c-erbB-3 are as effective as 
the control NLS of human lamin C in 
directing CPK from the cytoplasm (C) 
into the nucleus (N). 
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was found to be the full-length receptor and not a truncated
version (Lin et al., 2001; Bourguignon et al., 2002).
Although the list of nuclear localization of transmembrane
receptors is considerably long and includes the interleukin-1
receptor (Curtis et al., 1990), the NGF receptor (Rakowicz-
Szulczynska et al., 1988), the growth hormone receptor (Lo-
bie et al., 1994), and several endocytosis-related proteins
(Vecchi et al., 2001), one of the most well-known examples
is the nuclear translocation of the FGF receptor in response
to various stimuli (Maher, 1996; Stachowiak et al., 1996).
The lack of a clearly understood potential pathway for nu-
clear import of full-length transmembrane growth factor
receptors has raised some concerns about the relevance
of nuclear growth factor receptors (Oksvold et al., 2002).
However, a recent report demonstrated physical interaction
of the FGF receptor with the nuclear import factor importin
 
 
 
 (Reilly and Maher, 2001), suggesting that nuclear import
of the FGF receptor occurs via the importin 
 
 
 
 pathway. Al-
though we have no clear indication about potential nuclear
import pathways for c-erbB-3, we consider a similar path-
way at least possible.
Furthermore, it is evident that several polypeptide growth
factors can enter the cell nucleus (Keresztes and Boonstra,
1999). Correspondingly, FGF-3 was found to localize to the
cell nucleus, and an NLS was identified in the protein (An-
toine et al., 1997). Using the PSORT II software (http://
psort.nibb.ac.jp), we found a potential NLS near the NH
 
2
 
terminus (NLS-1) and the COOH terminus (NLS-2) of
the c-erbB-3 sequence. Reinhardt’s method (Reinhardt and
Hubbard, 1998) for cytoplasmic/nuclear discrimination pre-
dicted nuclear localization for c-erbB-3 with a reliability of
70%. Therefore, we constructed EGFP–mutant erbB-3 fu-
sion proteins and found that a tetra arginine repeat near the
COOH terminus of c-erbB-3 (NLS-2) was able to target
EGFP to the nucleus, whereas a similar potential NLS
(NLS-1) near the NH
 
2
 
 terminus of c-erbB-3 was inactive
(Fig. 6). Furthermore, transfer of NLS-2 to CPK, an exclu-
sively cytoplasmic protein (Frangioni and Neel, 1993), re-
sulted in efficient nuclear targeting of the fusion protein
(Fig. 7). These data clearly indicate that NLS-2 itself is suffi-
cient to confer nuclear targeting to heterologous proteins
different from c-erbB-3. Besides that, the c-erbB-3 sequence
(Kraus et al., 1989) contains several leucine-rich domains,
which fulfill the formal requirements for CRM1-dependent
nuclear export signals, and we observed that the CRM1 in-
hibitor LMB (Fukuda et al., 1997) can trap endogenous
c-erbB-3 in the nuclei of several different malignant and
nonmalignant cell lines of mammary epithelial origin, sup-
porting the idea that nuclear localization represents a general
property of c-erbB-3 and is not restricted to a specific cell
line. Additionally, we were able to demonstrate LMB-
induced nuclear accumulation of a transiently transfected
c-erbB-3–FLAG fusion protein. In the past, nuclear localiza-
tion of c-erbB-3 might have been overlooked in many cell
lines due to prominent cytoplasmic staining caused by active
nuclear export. The use of LMB allowed to selectively stop
this export and thus enabled visualization of c-erbB-3 in
the nuclei of several cell lines. In the absence of LMB, nu-
clear staining for c-erbB-3 was most intense in BT20 and
MDA468 cells and could not be further enhanced by LMB,
indicating that nuclear export pathways are not very active
in these cells.
 
Epithelial cell polarity and subnuclear localization 
of c-erbB-3
 
In contrast to solid substrate culture, MTSV1-7 grown on
permeable filters polarized and differentiated as determined
by localization of E-cadherin and ZO-1 (unpublished data)
and by the presence of microvilli (Fig. 5 C), which was ac-
companied by concentration of c-erbB-3 in the nucleoli,
where ribosome biosynthesis occurs, including transcription
of ribosomal genes and assembly of the ribosome subunits
(Shaw and Jordan, 1995). Previous studies showed that
growth factors like FGFs and parathyroid hormone–related
peptide can enter the nucleolus (Pederson, 1998). However,
to our knowledge no transmembrane growth factor receptor
has ever been observed within the nucleolus.
 
Effect of endogenous and exogenous HRG 
on the subcellular distribution of c-erbB-3
 
A previous report demonstrated that primary human mam-
mary epithelial cells express large amounts of HRG (Aguilar
et al., 1999). We examined immortalized nonmalignant
MTSV1-7 and MCF10A human mammary epithelial cells
for secretion of HRG and found it in one of them (MTSV1-
7) (Fig. 4). HRG is the cognate ligand for c-erbB-3 and
might affect its subcellular distribution in an autocrine and/
or paracrine fashion. Therefore, we blocked secreted HRG
with a neutralizing antibody, which caused nucleolar con-
finement of c-erbB-3 in MTSV1-7 grown on filters. Con-
versely, exogenous HRG
 
 
 
1 caused export of c-erbB-3 from
the nucleolus into the nucleoplasm and then into the cyto-
plasm. In contrast to a previous report demonstrating that
HRG contains a potential NLS and is transported into the
nucleus of the breast cancer cell line SKBR-3 (Li et al.,
1996), we found that neither endogenous nor exogenous
HRG enters the nucleus of nonmalignant MTSV1-7 cells
(Fig. 5 D). These data led us to suppose that HRG induces
nucleolar and nuclear export of c-erbB-3 by anchoring it to
nonnuclear structures, thus leading to a slow enrichment of
c-erbB-3 in the cytoplasm and its deprivation in the nu-
cle(ol)us. Although the exact mechanisms controlling the
equilibrium between nucle(ol)ar and nonnucle(ol)ar c-erbB-3
are still unknown, it still appears that HRG is crucial in de-
termining its balance by binding it outside the nucleus not al-
lowing its reentry. Interestingly, four tumor cell lines (MCF-
7, BT474, T47D, and BT483) spontaneously exhibited low
levels of nuclear c-erbB-3, whereas two others (BT20 and
MDA468) and two nonmalignant cell lines (MTSV1-7 and
MCF10A) revealed strong nuclear staining, possibly reflect-
ing different activation states of the c-erbB-3 pathway. Many
breast cancer cells exhibit overexpression/hyperactivation of
c-erbB-2, which is the major heterodimer partner of c-erbB-3
and plays a crucial role in controlling c-erbB-3 activation
and maybe subcellular localization. Accordingly, MDA468
are negative for c-erbB-2 and thus devoid of c-erbB-2/-3
heterodimers. On the other hand, BT20 cells overexpress
c-erbB-1, which competes with c-erbB-3 for heterodimeriza-
tion with c-erbB-2. It is thus very likely that these cells are
also very poor in active c-erbB-2/-3 heterodimers. Strikingly, 
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c-erbB-2 was invariably expressed in the cytoplasm and the
membrane, irrespective of stage of malignancy, the level of
baseline expression, and the culture conditions (unpublished
data), indicating that the subcellular distribution of c-erbB-3
is specific for this particular receptor.
Although the ultimate mechanisms of nucleocytoplasmic
shuttling of c-erbB-3 and its precise role in the nucleus re-
main to be elucidated, our data open up new perspectives on
the functions of c-erbB proteins. Together, c-erbBs may not
only represent membrane-anchored signal transducers with
crucial roles in malignant transformation and progression,
but as constituents of nucleolar structures they might also
regulate ribosome biosynthesis.
 
Materials and methods
 
Cell culture
 
The MTSV1-7 nonmalignant human mammary epithelial cell line (a gift
from Dr. J. Taylor-Papadimitriou, Imperial Cancer Research Fund, London,
UK) was maintained in DME supplemented with 10% FCS, 100 IU (
 
 
 
g)/ml
penicillin-streptomycin, 2 mM glutamine, 10 
 
 
 
g/ml insulin (GIBCO BRL),
and 5 
 
 
 
g/ml hydrocortisone (Sigma-Aldrich). The human breast cancer cell
lines MCF-7, BT474, T47D, MDA468, and BT20 (American Type Culture
Collection) were cultivated in DME containing 10% FCS, 100 IU (
 
 
 
g)/ml
penicillin-streptomycin, and 2 mM glutamine (standard medium). BT483
cells (American Type Culture Collection) were grown in standard medium
containing an additional 10 
 
 
 
g/ml insulin, whereas MCF10A nonmalig-
nant human mammary epithelial cells (American Type Culture Collection)
were maintained in serum-free MEGM (Clonetics) according to the manu-
facturer’s instructions.
 
LMB treatments
 
For immunofluorescence, cells were seeded at 10
 
4
 
/cm
 
2
 
 into 8-well glass
chamber slides (Nunc) and allowed to settle for 24 h. Media were re-
placed, and 20 ng/ml LMB (a gift from Dr. B. Wolff-Winiski, Novartis, Vi-
enna, Austria) in 0.1% methanol or solvent alone were added to the cells
and incubated for 24 h. c-erbB-3–FLAG–transfected MCF-7 cells were
treated for 24 h with 5 ng/ml LMB or solvent.
For fractionation experiments, MCF-7 cells were seeded into five 500-
cm
 
2
 
 plates and grown to 80% confluence. 5 ng/ml LMB was added to three
of the plates, whereas the remaining plates were treated with 0.1% metha-
nol for 24 h. These conditions were found previously to yield optimal nu-
clear localization of c-erbB-3 in MCF-7 cells, whereas toxicity was kept at
a minimum (unpublished data).
 
Flow cytometry
 
MCF-7, MDA468, T47D, and BT20 cells were rinsed with PBS, briefly
trypsinized, and washed with FACS
 
®
 
 buffer (1% BSA, 0.1% NaN
 
3
 
 in PBS).
All subsequent incubations and washings were performed in this buffer.
Labeling with 10 
 
 
 
g/ml of mouse monoclonal anti–c-erbB-3 antibody
(SGP1; Neomarkers) or irrelevant control mIgG (Dako) was performed for
30 min on ice. Washed cells were then labeled for 30 min on ice with goat
anti–mouse Ig-Alexa488 (1:200; Molecular Probes). Analysis was per-
formed with a FACScan
 
®
 
 (Becton Dickinson) equipped with CellQuest
software. For life gating, propidium iodide (0.5 
 
 
 
g/ml; Sigma-Aldrich) was
added to the cold cells immediately before measurement, and 5 
 
 
 
 10
 
3
 
nonpermeable cells per sample were measured. Results were expressed as
mean fluorescence intensity.
 
Nuclear and cytoplasmic fractions
 
Control and LMB-treated MCF-7 were washed twice with PBS, harvested
by scraping and centrifuged (1,850 
 
g, 10 min, 4 C), suspended in 5 packed
cell vol hypotonic buffer (10 mM Hepes, pH 7.9, 1.5 mM MgCl2, 10 mM
KCl, 0.2 mM PMSF, 0.5 mM DTT, protease inhibitors [1 tablet Complete
®
EDTAfree/50 ml, Roche]), recentrifuged, resuspended in 3 packed cell vol
hypotonic buffer, incubated on ice (10 min), homogenized (Dounce, type
B pestle, 25 strokes), and spun (3,300 g, 15 min, 4 C). The supernatant was
designated S1 and saved. The nuclear pellet was washed twice with 10 ml
hypotonic buffer and suspended in 0.5 packed nuclear vol low salt buffer
(20 mM Hepes, pH 7.9, 25% glycerol, 1.5 mM MgCl2, 20 mM KCl, 1 mM
EGTA, 0.2 mM PMSF, 0.5 mM DTT, 0.2% Triton X-100, 1 tablet Com-
plete
® Mini EDTAfree/10 ml). Then, 0.5 packed nuclear vol high salt buf-
fer (low salt buffer with 1.2 M KCl) were added, and nuclei were ho-
mogenized (25 strokes), extracted on a shaker (30 min, 4 C), and spun
(25,000 g, 30 min, 4 C). 1 U/ml  2-macroglobulin (Roche), which is un-
able to pass a 10-kD-cutoff dialysis membrane, was added to the superna-
tant and dialyzed (dialysis buffer [DB]; 20 mM Hepes, pH 7.9, 10% glyc-
erol, 300 mM KCl, 0.5 mM EGTA, 0.2 mM PMSF, 0.2% Triton X-100; 1 h,
4 C) in a slide-a-lyzer cassette (MWCO 10000; Pierce Chemical Co.). The
dialyzed nuclear extract was recentrifuged (25,000 g, 20 min, 4 C), ali-
quoted, and stored at  80 C.
Cytoplasmic extracts. Saved supernatant S1 was mixed with 0.11 vol
10  cytoplasmic extract buffer (300 mM Hepes, pH 7.9, 30 mM MgCl2,
1.4 M KCl, 2% Triton X-100), spun (100,000 g, 1 h, 4 C; S100 fraction),
and  2-macroglobulin was added before dialysis. The dialyzed fraction
was centrifuged (25,000 g, 20 min, 4 C) and stored as above.
For some experiments a simplified protocol was used. The supernatant S1
was divided into 2 aliquots, and cytoplasmic extract buffer with or without
Triton X-100 was added before centrifugation at 100,000 g. The superna-
tants were subjected to protein assay according to Bradford and used di-
rectly for Western blotting. The membrane pellet from the fraction without
Triton X-100 was dissolved by boiling (5 min, 95 C) in 400  l Laemmli
buffer, and insoluble components were removed by centrifugation before
10  l of this solution was used for Western blotting.
Immunoprecipitation
Concentration of nuclear and cytoplasmic protein (400  g each) from
LMB-treated or untreated MCF-7 cells was balanced with DB, which was
supplemented with 1 tablet Complete
® Mini EDTAfree/10 ml (DBC).
Gamma bind plus sepharose beads (Amersham Pharmacia Biotech) were
washed and resuspended to original vol with DBC. 10  l beads, 4  g anti–
c-erbB-3 (SGP1; Neomarkers) or murine IgG1 (Dako), and respective frac-
tion (400  g protein) were mixed, incubated on a shaker (1 h, 4 C),
washed five times (200  l DBC), spun (10,000 g, 1 min, 4 C), resuspended
in Laemmli buffer, boiled (5 min), and stored frozen.
Western blotting
Proteins were separated by 7.5% SDS-PAGE, and gels were equilibrated
for 30 min in blotting buffer (20% methanol, 380 mM glycine, 50 mM Tris,
0.1% SDS). Proteins were blotted onto polyvinylidene difluoride mem-
branes (New England Nuclear), which were then blocked for 1 h in 5%
BSA/PBS at room temperature (RT), washed with PBS containing 0.1%
Tween 20 (PBST), and immunostained for 3 h at RT in 1% BSA/PBS con-
taining the primary antibody: polyclonal anti–c-erbB-3 (0.2  g/ml, C17;
Santa Cruz Biotechnology, Inc.), polyclonal anti-CPK (cross-reactive with
human pyruvate kinase) (1:4,000; Convance), monoclonal anti–histone
H1 (0.2  g/ml; Neomarkers), monoclonal anti-calnexin (1:400; Affinity
BioReagents, Inc.), or monoclonal antitransferrin receptor (1  g/ml; Neo-
markers). Washed blots were labeled for 1 h with sheep anti–mouse or
donkey anti–rabbit Ig F(ab’)2-HRP conjugate (1:10,000 in 1% BSA/PBST;
Amersham Pharmacia Biotech), washed extensively in PBST, immersed in
ECL detection reagent (New England Nuclear), and exposed to X-Omat AR
film (Eastman Kodak Co.).
For the detection of secreted HRG, MTSV1-7 and MCF10A cells were
grown in serum-free MEGM. Conditioned culture supernatants were then
recovered and 10-fold concentrated with Centricon 10 concentrators
(Millipore). 10  l Laemmli buffer were added to 10  l of the concentrates
and boiled (5 min), separated by 10% SDS-PAGE, blotted, and immu-
nostained with 1  g/ml rabbit anti-HRG (Ab-2; Neomarkers) and donkey
anti–rabbit Ig F(ab’)2-HRP conjugate (1:10,000; Amersham Pharmacia
Biotech) as above.
Immunofluorescence (c-erbB, FLAG, and HRG)
Washed cells (PBS) were fixed in 2% paraformaldehyde (PFA) (5 min, RT),
permeabilized in methanol/acetone (1:1, 3 min,  20 C), air dried, and
stored at  80 C. Before use, cells were rehydrated in PBS (5 min, RT),
blocked in 5% sheep serum/PBS (30 min, RT), and washed again. Antibod-
ies (in 5% sheep serum/PBS, 1 h, RT) were against c-erbB-2 (10  g/ml
mouse monoclonal mAB-3; Oncogene Research Products), c-erbB-3 (10
 g/ml mouse monoclonal RTJ2; Neomarkers) (5  g/ml rabbit polyclonal
C17; Santa Cruz Biotechnology, Inc.) (10  g/ml rabbit polyclonal Ab-9;
Neomarkers), FLAG (20  g/ml, mouse monoclonal M2; Sigma-Aldrich),
and HRG  (10  g/ml goat polyclonal C18; Santa Cruz Biotechnology,
Inc.). Secondary antibodies were goat anti–mouse or goat anti–rabbit Ig-
Alexa488 or donkey anti–goat Ig-Alexa546 (1:200 in 5% sheep serum/PBS,
30 min, RT; Molecular Probes). Washed cells were embedded in Prolong
Antifade (Molecular Probes) and evaluated in an LSM400 confocal micro-
scope (ZEISS) with a thickness of the optical sections of 0.8  m.938 The Journal of Cell Biology | Volume 157, Number 6, 2002
Immunofluorescence (CPK)
For detection of CPK fusion proteins, fixed cells were quenched in 50 mM
glycine/PBS (5 min, RT). Blocking was performed with 10% goat serum in
PBS containing 0.2% NP-40 (30 min, RT). All subsequent washing and in-
cubation steps were performed as above in solutions containing 0.2% NP-
40 to suppress background staining caused by cross-reactivity of the antise-
rum with endogenous (human) pyruvate kinase (Frangioni and Neel, 1993).
The following antibodies were used: crude rabbit antiserum against CPK
(Convance, 1:500) and goat anti–rabbit Ig-Alexa488 (1:200; Molecular
Probes).
Filter assay
MTSV1-7 cells were plated at 10
5 into 25 mm Anopore-Inserts (Nunc).
Neutralizing anti-HRG (Ab-2, 10  g/ml; Neomarkers) was added where in-
dicated. After 48 h, cells were washed and exposed for the indicated times
to 1 nM recombinant HRG 1 (Neomarkers). Filters were broken out at the
end of the experiments, cut, and processed as above.
Immuno EM
MTSV1-7 grown in culture flasks were fixed with 2.5% PFA/0.5% glutaral-
dehyde in 0.1 M Soerensen buffer (SB; 30 min, 4 C) and washed 3   10
min with SB. Two batches of MTSV1-7 grown on filter were prepared: one
treated with neutralizing anti-HRG and one with subsequent exposition to
1 nM HRG 1 for 24 h. Small pieces of filters were fixed with 4% PFA/
0.5% glutaraldehyde in 0.1 M SB (30 min, 4 C) and washed three times
with SB. Filters and MTSV1-7 in suspension were embedded in the hydro-
philic resin LRWhite (London Resin Company). Ultrathin sections of
MTSV1-7 cells were mounted on meshed gold grids; sections of the filters
were mounted on Formvar-coated gold grids.
Grids were preincubated in PBS plus 1% BSA plus 1% normal goat se-
rum, pH 7.4 (PBSB; 30 min, RT), incubated overnight with anti–c-erbB-3
(monoclonal RTJ2, 10  g/ml in PBSB, and rabbit polyclonal Ab-9, 5  g/ml
in PBSB; 4 C), washed thoroughly in PBST, pH 7.4 and 8.2, labeled with
10 nm gold-conjugated goat anti–mouse or goat anti–rabbit IgG (1:40 in
PBSB, pH 8.2; British BioCell), and washed in PBST, pH 8.2, and in dis-
tilled water. Contrast was enhanced with 2% aqueous uranyl acetate (30
min), and sections were evaluated with a Jeol EM1200 electron micro-
scope equipped with a digital camera (BioScan 792; Gatan). For controls,
the primary antibody was omitted. Signal distribution over cytoplasm and
nucleus was quantified by counting gold particles per respective area in 10
randomly chosen cells per sample. The area was measured with the help
of morphometry software (KS400; Kontron). For statistical comparison of
datasets of RTJ2, Ab-9 and control series Student’s t test was applied. Nor-
mal (Gaussian) distribution of datasets was checked using the R/s test.
EGFP fusion protein construction and analysis
A plasmid containing full-length c-erbB-3 was linearized by complete XbaI
digestion, and the signal peptide was removed by partial SmaI digestion.
pEGFP-C1 (CLONTECH Laboratories, Inc.) was digested with Ecl136II and
XbaI before ligation.
Two COOH-terminal deletion mutants of the c-erbB-3 cDNA were con-
structed by cleaving the c-erbB-3 insert at the unique Ecl136II and XbaI or
the EcoRI and XbaI restriction sites. The EcoRI and XbaI sites of c-erbB-3
and pEGFP-C1 were then filled in, respectively, and the COOH-terminally
truncated c-erbB-3 inserts were ligated with the pEGFP-C1 vector. This
yielded proteins with EGFP fused to amino acids 1–1,088 (Ecl136II) or 1-74
(EcoRI) of c-erbB-3.
In addition, the COOH terminus of c-erbB-3 was fused to EGFP using the
Ecl136II site of c-erbB-3, the filled-in HindIII site of pEGFP-C1 and the XbaI
sites of both vector and insert, yielding a construct containing amino acids
1,089–1,323 of c-erbB-3 downstream of EGFP. Site-specific mutagenesis
(R1184S/R1185G) of the latter construct was done with the Quick-Change
kit (Stratagene) according to the manufacturer’s protocol using the follow-
ing oligonucleotides: 5 -GGTGGACTGTGCCTTCCGCTCCGGTTCATGT-
ATTC-3  and 5 -GAATACATGAACCGGAGCGGAAGGCACAGTCCACC-
3 . Presence of the double mutation was verified by sequencing.
MTSV1-7 cells were seeded and transfected using Effectene (QIAGEN)
adhering to manufacturer’s protocols. 24 h after transfection, cells were
washed, fixed with 2% PFA as above, embedded in Mowiol/DABCO, and
evaluated by confocal microscopy as described above.
FLAG fusion protein construction and analysis
A vector containing full-length c-erbB-3 (supplied by F. Wouters, European
Molecular Biology Laboratory, Heidelberg, Germany) was used in order
to fuse the FLAG peptide to the COOH terminus of c-erbB-3. The se-
quence coding for the FLAG peptide was supplied using the following
oligonucleotides: 5 -CGACTACAAGGACGACGATGACAAGTGAGCTCGC-
3  and 5 -GGCCGCGAGCTCACTTGTCATCGTCGTCCTTGTAGTCGAT-
3 , which were dissolved at 200  M in 10 mM Tris/HCl, 150 mM NaCl,
pH 7.5, and mixed in equal volumes. Annealing was performed by heating
the mixture to 94 C and cooling it down to 25 C over a period of 1 h be-
fore ligation to c-erbB-3. MCF-7 cells were seeded and transfected using
Fugene6 (Roche) according to the supplied protocol. 1 d after transfection,
cells were subjected to LMB treatment. Immunofluorescence microscopy
was performed as described above.
CPK fusion protein construction and analysis
The p3PK vector, which was used to create fusion proteins of CPK with
various human c-erbB-3 fragments, and a positive control plasmid for nu-
clear localization containing CPK fused to the heterologous NLS of human
lamin C (p3PK-NLS-Lamin C) were supplied by Dr. J. V. Frangioni (Beth Is-
rael Deaconess Medical Center, Boston, MA). The sequence coding for
NLS-2 of c-erbB-3 (RRRRHSP*) was cloned using the following oligonucle-
otides: 5 -GATCCCGGAGGAGAAGGCACAGTCCATGAG-3  and 5 -AAT-
TCTCATGGACTGTGCCTTCTCCTCCGG-3 , which were annealed as
above. Using standard procedures, this dsDNA was then ligated to p3PK,
which had been digested with EcoRI and BamHI in order to yield a CPK-
NLS-2 fusion protein.
Another construct was produced by digesting p3PK with BamHI, filling
in, redigesting with XbaI, and dephosphorylation. The insert (COOH-ter-
minal end of c-erbB-3, amino acids 915–1,323) was prepared by digesting
c-erbB-3 with BglII, filling in, and redigesting with XbaI. Ligation was per-
formed as above, yielding a construct of CPK fused to the COOH terminus
(amino acids 915–1,323) of c-erbB-3 (CPK-erbB3CT). Transfection of
MTSV1-7 cells with Effectene and immunofluorescence microscopy were
performed as described above.
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